GSTM1 and kidney disorder: The most recent European Renal Best Practice [3] and Kidney Disease Improving Global Outcomes [4] guidelines recommend that ESA treatment be initiated at hemoglobin (Hb) levels below 10 g/dL but be withheld when Hb reaches 11.5 g/dL or higher.